Literature DB >> 16537618

Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.

Isabelle Desombere1, Annick Willems, Yvonne Gijbels, Geert Leroux-Roels.   

Abstract

Hepatitis B virus surface antigen (HBsAg) is a complex macromolecular particle composed of glycoproteins and lipids. The latter, representing 25% of the particle mass, are of host origin and determine the solubility, stability, and, indirectly, B-cell immunogenicity of HBsAg. HBsAg is a T-cell-dependent immunogen that does not elicit a detectable humoral immune response in 5% of HBsAg vaccine recipients and in most subjects suffering from chronic hepatitis B. We investigated the influence of the lipid content on the antigenicity of the particle. Lipids were partially removed from HBsAg by treatment with beta-D-octyl glucoside and density centrifugation. Sham treatment consisted of density centrifugation of HBsAg only. We compared the in vitro proliferative responses of established T-cell lines and nonfractionated peripheral blood mononuclear cells (PBMC) from HBsAg vaccinees and chronic HBV patients when stimulated with partially delipidated HBsAg, untreated HBsAg, or sham-treated HBsAg. In all experiments, delipidated HBsAg turned out to be 10 to 100 times more antigenic than its untreated or sham-treated counterpart. Remarkably, PBMC from vaccine nonresponders or chronic HBV patients displayed a proliferative response towards delipidated HBsAg, whereas native HBsAg never induced a response. A series of control experiments demonstrated that this enhancement of T-cell antigenicity was HBsAg specific and directly linked to lipid extraction. Nonspecific adjuvant effects of any kind could be ruled out. In vivo evaluation in mice demonstrated that delipidated particles lose most of their B-cell antigenicity. However, when native and delipidated particles were mixed, these mixtures induced equal or slightly superior anti-HBs responses to those induced by the same quantity of native HBsAg alone. In conclusion, our data show that partial delipidation of HBsAg strikingly increases the T-cell antigenicity of this unique viral antigen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537618      PMCID: PMC1440404          DOI: 10.1128/JVI.80.7.3506-3514.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels.

Authors:  J Heukeshoven; R Dernick
Journal:  Electrophoresis       Date:  1988-01       Impact factor: 3.535

2.  Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule.

Authors:  E Celis; R W Karr
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  The topology of the S protein in the yeast-derived hepatitis B surface antigen particles.

Authors:  N Sonveaux; K Conrath; C Capiau; R Brasseur; E Goormaghtigh; J M Ruysschaert
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

4.  Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines.

Authors:  G Leroux-Roels; E Van Hecke; W Michielsen; P Voet; P Hauser; J Pêtre
Journal:  Vaccine       Date:  1994-07       Impact factor: 3.641

5.  Isolation and characterization of the major protein and glycoprotein of hepatitis B surface antigen.

Authors:  D L Peterson
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

6.  Development of a hepatitis B vaccine from transformed yeast cells.

Authors:  J Pêtre; F Van Wijnendaele; B De Neys; K Conrath; O Van Opstal; P Hauser; T Rutgers; T Cabezon; C Capiau; N Harford
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

7.  Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg.

Authors:  D R Milich; F V Chisari
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

8.  Hepatitis B surface antigen. Role of lipids in maintaining the structural and antigenic properties of protein components.

Authors:  F Gavilanes; J Gomez-Gutierrez; M Aracil; J M Gonzalez-Ros; J A Ferragut; E Guerrero; D L Peterson
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

9.  A topological model for hepatitis B surface antigen.

Authors:  H J Stirk; J M Thornton; C R Howard
Journal:  Intervirology       Date:  1992       Impact factor: 1.763

10.  The immune response to hepatitis B vaccine in humans: inheritance patterns in families.

Authors:  M S Kruskall; C A Alper; Z Awdeh; E J Yunis; D Marcus-Bagley
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  4 in total

1.  Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.

Authors:  Yu-Cheng Lin; Shu-Tin Hsiao; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

2.  Biochemical and biophysical characterization of maize-derived HBsAg for the development of an oral vaccine.

Authors:  Shweta Shah; Celine A Hayden; Maria E Fischer; A Gururaj Rao; John A Howard
Journal:  Arch Biochem Biophys       Date:  2015-10-28       Impact factor: 4.013

3.  Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism.

Authors:  Nadine van Montfoort; Evelyn van der Aa; Aniek van den Bosch; Hilde Brouwers; Thomas Vanwolleghem; Harry L A Janssen; Hassan Javanbakht; Sonja I Buschow; Andrea M Woltman
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

Review 4.  Immunogenicity of infectious pathogens and vaccine antigens.

Authors:  Siddhartha Mahanty; Antoine Prigent; Olivier Garraud
Journal:  BMC Immunol       Date:  2015-05-29       Impact factor: 3.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.